Stock ALPMY ASTELLAS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Astellas Pharma Inc. OTC Markets

Equities

ALPMY

US04623U1025

Market Closed - OTC Markets
Other stock markets
 20:59:59 23/05/2024 BST 		5-day change 1st Jan Change
9.86 USD +1.54% Intraday chart for Astellas Pharma Inc. +1.86% -17.14%
05-21 Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies CI
05-16 Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea DJ

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Astellas Confirms Unfavorable District Court Decision Concerning its Motion for a Preliminary Injunction against Lupin and Zydus Generic Versions of MyrbetriqTM
AQ
U.S. FDA Accepts Astellas' Supplemental New Drug Application for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy
AQ
Astellas VYLOY Approved in Japan for Treatment of Gastric Cancer
AQ
Iveric Bio - Astellas Receives Permanent J-code for IZERVAY for Geographic Atrophy
AQ
Astellas Receives Positive CHMP Opinion for XTANDI in Additional Recurrent Early Prostate Cancer Treatment Setting
AQ
Xyphos Biosciences enters research collaboration and license agreement with Kelonia Therapeutics
AQ
Astellas Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer
AQ
Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager
BU
Pfizer Inc. - PADCEV with KEYTRUDA Approved by FDA as the First and Only ADC plus PD-1 to Treat Advanced Bladder Cancer
AQ
Astellas Pharma Inc. - PADCEV with KEYTRUDA Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
AQ
Astellas Pharma Inc. - EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children
AQ
Astellas secures EC approval for VMS treatment, fezolinetant
AQ
Astellas VEOZA Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause
AQ
Outgoing Japan envoy regrets not being able to rescue detained man
AQ
Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies
AQ
Astellas Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
AQ
Japan envoy meets citizen detained in China over spying for 1st time
AQ
Astellas Pharma Inc. - University of Tsukuba and Astellas Confirm a Strategic Partnership
AQ
Pfizer and Astellas XTANDI Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
AQ
KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug for Systemic Oncolytic Virus ASP1012 for Phase I Clinical Trials for Locally Advanced or Metastatic Solid Tumors
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4503 Stock
  4. ALPMY Stock
  5. News Astellas Pharma Inc.
  6. Press Releases